DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23621668 | https://www.ncbi.nlm.nih.gov/pubmed/22954177 | https://www.ncbi.nlm.nih.gov/pubmed/24525548 | https://www.ncbi.nlm.nih.gov/pubmed/25777582 | https://www.ncbi.nlm.nih.gov/pubmed/23401746
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23621668 | https://www.ncbi.nlm.nih.gov/pubmed/22954177 | https://www.ncbi.nlm.nih.gov/pubmed/24525548 | https://www.ncbi.nlm.nih.gov/pubmed/25777582 | https://www.ncbi.nlm.nih.gov/pubmed/23401746
CB-13 is a cannabinoid drug, which acts as a potent agonist at both the CB1 and CB2 receptors, but has poor blood-brain barrier penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as catalepsy only appearing at much higher dose ranges. CB-13 displays antihyperalgesic activity in a rat model of neuropathic pain with no CNS side effects.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL218 |
6.1 nM [EC50] | ||
Target ID: CHEMBL253 |
27.9 nM [EC50] | ||
Target ID: CHEMBL3397 |
80800.0 nM [IC50] | ||
Target ID: CHEMBL218 |
10.0 nM [Ki] | ||
Target ID: CHEMBL253 |
42.0 nM [Ki] | ||
Target ID: CHEMBL4794 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Sativex Approved UseUnknown |
|||
| Primary | Sativex Approved UseUnknown |
|||
| Primary | Sativex Approved UseUnknown |
|||
| Primary | Sativex Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. | 2007 Aug 9 |
|
| Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. | 2014 May 25 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29631
Created by
admin on Sat Dec 16 00:22:25 GMT 2023 , Edited by admin on Sat Dec 16 00:22:25 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB180792
Created by
admin on Sat Dec 16 00:22:25 GMT 2023 , Edited by admin on Sat Dec 16 00:22:25 GMT 2023
|
PRIMARY | |||
|
4793
Created by
admin on Sat Dec 16 00:22:25 GMT 2023 , Edited by admin on Sat Dec 16 00:22:25 GMT 2023
|
PRIMARY | |||
|
C71037
Created by
admin on Sat Dec 16 00:22:25 GMT 2023 , Edited by admin on Sat Dec 16 00:22:25 GMT 2023
|
PRIMARY | |||
|
NABIXIMOLS
Created by
admin on Sat Dec 16 00:22:25 GMT 2023 , Edited by admin on Sat Dec 16 00:22:25 GMT 2023
|
PRIMARY | |||
|
44148067
Created by
admin on Sat Dec 16 00:22:25 GMT 2023 , Edited by admin on Sat Dec 16 00:22:25 GMT 2023
|
PRIMARY | |||
|
DTXSID40972015
Created by
admin on Sat Dec 16 00:22:25 GMT 2023 , Edited by admin on Sat Dec 16 00:22:25 GMT 2023
|
PRIMARY | |||
|
56575-23-6
Created by
admin on Sat Dec 16 00:22:25 GMT 2023 , Edited by admin on Sat Dec 16 00:22:25 GMT 2023
|
PRIMARY | |||
|
K4H93P747O
Created by
admin on Sat Dec 16 00:22:25 GMT 2023 , Edited by admin on Sat Dec 16 00:22:25 GMT 2023
|
PRIMARY | |||
|
UU-89
Created by
admin on Sat Dec 16 00:22:25 GMT 2023 , Edited by admin on Sat Dec 16 00:22:25 GMT 2023
|
PRIMARY |
All of the following components must be present:
SUBSTANCE RECORD
